ArticleCancer medicine2026
Survival of Colon Cancer in a Population-Based Cohort Study: A Comprehensive Analysis of Location of the Primary Tumor.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Disparities in survival between left- versus right-sided colon cancer have been reported. We studied the role of sidedness on survival of colon cancer across tumor biomarkers subgroups in a population-based cohort established using the Geneva Cancer Registry database. Our study included 3503 colon cancer cases diagnosed between 1985 and 2013. Right-sided colon cancers (ICD-O codes C18.0, C18.2-18.4) and left-sided colon cancers (ICD-O codes C18.5-18.7) were compared. Five-year net survival was estimated using the Pohar-Perme estimator. Flexible hazard models evaluated the association of survival with sidedness adjusted for patient, tumor, and treatment characteristics. Left-sided colon cancers were more frequent than right-sided colon cancers (53% vs. 47%). Right-sided colon cancer cases were older and more often women, less frequently of stage I or well differentiated. Left-sided colon cancer had a higher 5-year net survival than right-sided colon cancer (66% vs. 59%, p < 0.001). In a multivariable model, patients with a left-sided tumor had a 25% reduction in 5-year mortality compared with right-sided tumors (excess hazard ratio [eHR]: 0.75, 95% confidence interval [CI]: 0.63-0.89, p = 0.001). This association remained significant only among stage IV while not among stages I-III. Among a subgroup of 2438 cases, stratification on tumor molecular biomarkers confirmed the better prognosis of left-sided colon cancer versus right-sided colon cancer among microsatellite stable (MSS) tumors, tumors with BRAF wild-type (BRAFwt), and iCMS2 tumors. This study shows the importance of sidedness for prognosis and treatment considerations in addition to tumor biomarkers. Further research is needed to assess the molecular mechanisms underlying these differences between left and right colon cancer to address the prognostic gap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.